Skip to main content
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNO-ONCOLOGY
IMMUNOTHERAPIES
NUCLEIC ACID THERAPEUTICS
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
BRUSSELS, EU
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNO-ONCOLOGY
IMMUNOTHERAPIES
NUCLEIC ACID THERAPEUTICS
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
BRUSSELS, EU
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Home
OUR XCHANGES
BY TOPIC
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNO-ONCOLOGY
IMMUNOTHERAPIES
NUCLEIC ACID THERAPEUTICS
OLIGONUCLEOTIDE THERAPEUTICS
BY LOCATION
BOSTON, USA
SAN FRANCISCO, USA
MARYLAND, USA
SAN DIEGO, USA
PHILADELPHIA, USA
BRUSSELS, EU
INDUSTRY EXPERTS
ADVANCED THERAPIES
AI IN DRUG DISCOVERY
ANTIBODY THERAPEUTICS
IMMUNOTHERAPIES
OLIGONUCLEOTIDE THERAPEUTICS
NEWS XCHANGE
PARTNERSHIPS
OUR PARTNERS
BECOME A PARTNER
ABOUT US
GET TO KNOW US
MEET THE TEAM
GALLERY
CONTACT US
Industry Experts
Loading
Lars Linden
VP, Therapeutic Antibodies,
Bayer Pharmaceuticals
Sessions
18-Nov-2024
09:05– 10:05
Selecting disease-specific antigens to minimise ADC toxicity to healthy cells
LinkedIn
YouTube
Search
Search
Search
Username *
Password *
Login
)
